NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
5,790 trialsNCT02642809 2026-03-18
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Washington University School of Medicine
Phase 1 Completed
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT03292289 2026-03-17
QUALIPRO
Centre Oscar Lambret
Phase NA Completed
NCT02437656 2026-03-16
METCAP
Centre Oscar Lambret
Phase 2 Completed
NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03151213 2026-03-13
pregabalin
Tanta University
Phase 4 Completed
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT03223779 2026-03-12
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03367247 2026-03-10
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Phase NA Completed
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04194268 2026-03-10
PACK
University Hospital Heidelberg
Phase NA Completed
NCT07460596 2026-03-10
Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT00102011 2026-03-09
00-046
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT05162846 2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT03259763 2026-03-06
EUS-GE vs ES for Palliation of Gastric Outlet Obstruction
Johns Hopkins University
Phase NA Completed
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT06184867 2026-03-06
CATALYST
Rutgers, The State University of New Jersey
Phase NA Completed
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT05432492 2026-03-04
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Akeso
Phase 2 Completed
NCT06955468 2026-03-04
Prime GOC
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT06263205 2026-03-03
Dressing
Fudan University
Phase NA Completed
NCT07180303 2026-03-03
CRC-RPHC
The First Affiliated Hospital with Nanjing Medical University
Phase NA Completed
NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04238715 2026-03-02
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Inc.
Phase 2 Completed
NCT03510858 2026-02-27
Randomized Controlled Trial on Colorectal Cancer Screening Among Quality Circles of Primary Care Physicians
University of Bern
Phase NA Completed
NCT03640208 2026-02-27
Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
Case Comprehensive Cancer Center
Phase NA Completed
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT04526106 2026-02-27
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
Phase 1/2 Completed
NCT05304936 2026-02-27
HCW9218 for Advanced Pancreatic Cancer
ImmunityBio, Inc.
Phase 1/2 Completed
NCT07437573 2026-02-27
KLASS-09
Korea University Guro Hospital
Phase 3 Completed
NCT04761185 2026-02-25
Raltitrexed in HIPEC
Fudan University
Phase 1 Completed
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT05424068 2026-02-25
Rehabilitation for People With Advanced Cancer
University Health Network, Toronto
Phase NA Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01013649 2026-02-23
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed